Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 8,625 matching trials from the live ClinicalTrials.gov search.
Conditions
Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery
Interventions
Thoracic, Abdominal, Custom Device, Illiac Artery
Device
Lead sponsor
Vascutek Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
17
States / cities
Long Beach, California • Aurora, Colorado • Colorado Springs, Colorado + 14 more
Conditions
HIV-1
Interventions
Maraviroc + Zidovudine/Lamivudine, Efavirenz + Zidovudine/Lamivudine, Maraviroc (UK-427,857) + Zidovudine/Lamivudine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
916 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
46
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 33 more
Conditions
Graft Versus Host Disease (GVHD)
Interventions
Alpha-1 antitrypsin (AAT), Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
25
States / cities
Stanford, California • Gainesville, Florida • Tampa, Florida + 20 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Allergic Disease Onset Prevention Study

NCT05003804
Conditions
Atopic Dermatitis, Type 1 Hypersensitivity
Interventions
STMC-103H, Placebo
Biological
Lead sponsor
Siolta Therapeutics, Inc.
Industry
Eligibility
0 Days to 14 Days
Enrollment
283 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
24
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Conditions
Breast Cancer
Interventions
Vinorelbine, Trastuzumab, Avelumab, Utomilumab
Drug
Lead sponsor
Adrienne G. Waks
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 12 more
Conditions
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
Interventions
LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
42
States / cities
Gilbert, Arizona • Phoenix, Arizona • Springdale, Arkansas + 31 more
Conditions
Severe Sepsis
Interventions
Drotrecogin alfa (activated)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fresno, California + 14 more
Active, not recruiting Not applicable Interventional Results available

TRILUMINATE Pivotal Trial

NCT03904147
Conditions
Tricuspid Regurgitation
Interventions
TriClipTM Device
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more
Conditions
Gastroesophageal Cancer, Adenocarcinoma
Interventions
Pembrolizumab, Abemaciclib
Drug
Lead sponsor
Nataliya Uboha
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Indianapolis, Indiana • Iowa City, Iowa • New Brunswick, New Jersey + 1 more
Conditions
Pancreatic Adenocarcinoma, Borderline Resectable Adenocarcinoma of the Head of the Pancrease
Interventions
radiation therapy, surgery, mFOLFIRINOX, FOLFOX
Radiation · Procedure · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
154
States / cities
Mobile, Alabama • Antioch, California • Berkeley, California + 122 more
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2013
U.S. locations
15
States / cities
Urbana, Illinois • Indianapolis, Indiana • Cedar Rapids, Iowa + 10 more
Conditions
Lung Transplant
Interventions
Exercise
Other
Lead sponsor
Indiana University Health Methodist Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Implementation Research, Depressive Disorder, ANXIETY DISORDERS (or Anxiety and Phobic Neuroses), Conduct Disorders in Children, Pediatric Mental Health Services
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
5 Years and older
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Large-Scale Implementation of a Decision Aid About Colorectal Cancer Screening

NCT06597955
Conditions
Colorectal Cancer Screening
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Terminated No phase listed Observational Accepts healthy volunteers

Role of Tissue Oxygenation and the miR-210 Gene In Wound Healing

NCT02024243
Conditions
Non-Diabetic Patients, Wound Leg, Chronic Ulcer Leg/Foot
Interventions
Not listed
Lead sponsor
Chandan Sen
Other
Eligibility
30 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
3
States / cities
Indianapolis, Indiana • Columbus, Ohio
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage III Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
Interventions
Filgrastim, Laboratory Biomarker Analysis, Pegfilgrastim, Topotecan Hydrochloride, Veliparib
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
78
States / cities
Orange, California • Aurora, Colorado • Hartford, Connecticut + 56 more
Terminated Not applicable Interventional Results available

Comparison of AmblyzTM Glasses and Patching for Amblyopia

NCT01973348
Conditions
Amblyopia
Interventions
4-hour AmblyZ glasses, 12-hour AmblyZ glasses, 2-hour patching, 6-hour patching
Device
Lead sponsor
Indiana University
Other
Eligibility
3 Years to 8 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel, Carboplatin plus Paclitaxel
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
926 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
80
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 69 more
Conditions
Non-Small Cell Lung Cancer
Interventions
pictilisib, Placebo, bevacizumab, carboplatin, paclitaxel
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
44
States / cities
Birmingham, Alabama • Rogers, Arkansas • Encinitas, California + 37 more
Conditions
Adult Intracranial Neoplasm, Vascular: Intracranial
Interventions
Fluorescein Sodium
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Indianapolis, Indiana • Norfolk, Virginia
Completed Phase 4 Interventional Results available

Retreatment of Recurrent Dupuytren's Contractures

NCT01498640
Conditions
Dupuytren's Disease
Interventions
Collagenase clostridium histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Phoenix, Arizona • Rockford, Illinois • Indianapolis, Indiana + 4 more
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis
Biological · Other
Lead sponsor
Morphotek
Industry
Eligibility
13 Months to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
20
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 17 more
Conditions
Leukemia
Interventions
cytarabine, dexamethasone, etoposide, idarubicin, ifosfamide, leucovorin calcium, mesna, pegaspargase, therapeutic hydrocortisone, thioguanine, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy, Methotrexate
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
30
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 23 more
Conditions
Hidradenitis Suppurativa
Interventions
Bermekimab, Adalimumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
22
States / cities
Phoenix, Arizona • Fountain Valley, California • Fremont, California + 19 more